The Plan Behind MRD’s New CTO

Mount Ridley Mines (ASX: MRD) has spent 2026 counting what’s in its ground. A scandium resource in January, heavy rare earths in March, with gallium alongside.

By autumn the company had JORC numbers on three of the minerals the West is scrambling for, from one shallow deposit 25km from the port at Esperance, and a share price sitting at 2.1 cents.

This morning’s announcement is about what happens to all that metal. And it reads like a company that has stopped thinking of itself as an explorer.

MRD has made Chris Larder its chief technology officer, and the board tied his 24 million performance rights to a set of milestones that would look at home at a technology company. Patents. Pilot production. Licensing deals. An IP sale with an eight-figure price on it.

A performance right only turns into a share if its condition is met. MRD set five conditions. Hit them, and 2.1 cents won’t be the number we’re writing about.

Who Is Chris Larder, Mount Ridley’s New CTO?

Larder has spent 30 years on WA processing plants, with time at Alcoa’s Wagerup refinery, which produces gallium, and Lynas’ Mt Weld rare earth operation. Those are the two plants in the state that already process what MRD has in the ground at Grass Patch. We first wrote about him joining MRD back in April.

If you sat down to write the job ad for this role, you’d end up describing his CV.

The clay at Grass Patch is shallow enough to dig with an excavator, and getting the metal out is meant to be simple too, a mild acid wash that rinses it off.

China built its grip on heavy rare earths from deposits like this in its southern provinces, and the wash is what makes them the cheapest producers going.

When the wash doesn’t take, the project stops. Plenty of juniors have drilled out a clay resource and never got the metal off it at a sensible cost.

That’s the work Larder has been running at the Nagrom lab in Perth since May. The early rounds came back with the right lean to them, the heavy rare earths rinsing out ahead of the lights. Dysprosium and terbium, the two most valuable metals in MRD’s ground, were first off.

Eight months ago he was a consultant designing a lab program. He now owns the company’s whole processing pathway, and the board has spelled out what it wants from him.

The Vesting Conditions on MRD’s 24 Million Performance Rights

We nearly filed this one under executive appointments. The table on page two pulled us back in.

Larder’s rights come in five tranches, each with its own trigger:

• 2 million vest at a 6 cent average share price, with six months’ service
• 3 million vest when MRD files a provisional patent over its own process technology, with the company named as sole applicant
• 4 million vest when that technology is licensed to an outside party, or when a pilot plant produces mixed rare earth oxide at 99% purity using what the document calls “the MRD owned Leach Process IP”
• 10 million, the biggest tranche, vest at a 15 cent average share price, with the patent and pilot conditions already met
• 5 million vest when MRD sells or licenses IP developed by Larder for at least $10 million

Strung together, the conditions are MRD’s plan: file a patent, prove the process at pilot scale, license it, then sell it. The board wrote it into Larder’s pay.

What the Milestones Would Mean for MRD

Each hurdle in that table creates a bigger company than the one trading today.

MRD last closed at 2.1 cents, worth about $29 million. The first hurdle at 6 cents is nearly triple that, roughly an $85 million company on today’s share count.

The patent tranche would hand MRD a processing method it owns outright, with its name alone on the filing. It’d be a rare feat for a small-cap.

The pilot tranche means Grass Patch clay has been turned into a 99% pure rare earth oxide, which is the form defence and magnet buyers pay for.

The 15 cent hurdle values MRD somewhere past $200 million. And the last tranche is a $10 million payment for the IP, a third of today’s entire market cap.

Boards set hurdles where they believe a good operator can reach them. Larder took these ones, and the board offered them, which says plenty about how both sides read the early lab work.

Sunrise Energy Metals (ASX: SRL) paired its scandium deposit with its own processing technology, landed Lockheed Martin as a customer, and now trades north of $2 billion after a 2,000% year.

Our Take

Vesting conditions are targets, and boards hand out performance rights that die in a drawer all the time.

The wash has to keep behaving as the sample sizes grow, which is where plenty of clay projects have come unstuck. A filed patent still has to be granted, and a granted patent earns nothing until someone pays to use it.

The downstream ambition has been building all year, through the ore samples sitting with Lawrence Livermore, one of the US government’s three nuclear security laboratories, and the CSIRO work on where MRD’s scandium could sell.

Larder has watched all of it from the inside, and this week he signed up to a pay packet that only works if the process he’s building gets patented and sold. We’d hazard a guess that a man who has seen the lab data doesn’t take that bet lightly.

MRD says the testwork results will be reported as they arrive. We’ll be reading the next one closely.